Journal Cover Journal of Clinical and Experimental Hepatology
  [SJR: 0.283]   [H-I: 7]   [4 followers]  Follow
   Full-text available via subscription Subscription journal
   ISSN (Print) 0973-6883
   Published by Elsevier Homepage  [3118 journals]
  • INASL Position Statements on Prevention, Diagnosis and Management of
           Hepatitis B Virus Infection in India: The Andaman Statements
    • Authors: Anil Arora; Shivaram P. Singh, Ashish Kumar, Vivek A. Saraswat, Rakesh Aggarwal, Manisha Bangar, Pradip Bhaumik, Harshad Devarbhavi, Radha K. Dhiman, Vinod K. Dixit, Ashish Goel, Bhabadev Goswami, Dharmesh Kapoor, Kaushal Madan, Jimmy Narayan, Sandeep Nijhawan, Gaurav Pandey, Ramesh R. Rai, Manoj K. Sahu, Neeraj Saraf, Shalimar, Thrivikrama Shenoy, Varghese Thomas, Manav Wadhawan, INASL Hepatitis B Taskforce
      Abstract: Hepatitis B virus (HBV) infection is one of the major causes of morbidity, mortality and healthcare expenditure in India. There are no Indian consensus guidelines on prevention, diagnosis and management of HBV infection. The Indian National Association for Study of the Liver (INASL) set up a taskforce on HBV in 2016, with a mandate to develop consensus guidelines for diagnosis and management of HBV infection, relevant to disease patterns and clinical practices in India. The taskforce first identified contentious issues on various aspects of HBV management, which were allotted to individual members of the taskforce who reviewed them in detail.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-09
      DOI: 10.1016/j.jceh.2017.12.001
  • Evaluation of Splenic Stiffness in Patients of Extrahepatic Portal Vein
           Obstruction Using 2D Shear Wave Elastography: Comparison with
           Intra-Operative Portal Pressure
    • Authors: Kumble S. Madhusudhan; Ragini Kilambi, Shalimar, Sujoy Pal, Raju Sharma, Deep N. Srivastava
      Abstract: To compare splenic stiffness (SS) with intra-operative portal pressures (PPs) in patients of extrahepatic portal vein obstruction (EHPVO).
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-04
      DOI: 10.1016/j.jceh.2017.12.002
  • Race and Gradient Difference Are Associated with Increased Risk of Hepatic
           Encephalopathy Hospital Admission After Transjugular Intrahepatic
           Portosystemic Shunt Placement
    • Authors: Michael W. Rowley; Myunghan Choi, Steve Chen, Kevin Hirsch, Anil B. Seetharam
      Abstract: Hepatic encephalopathy (HE) is a well-recognized complication of transjugular intrahepatic portosystemic shunt (TIPS) placement. The aim of this investigation was to evaluate incidence and predictors of post-TIPS HE necessitating hospital admission in a non-clinical trial setting.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-03
      DOI: 10.1016/j.jceh.2017.12.003
  • Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We
           at the End of the Road'
    • Authors: Chalermrat Bunchorntavakul; Robert Mitrani, K. Rajender Reddy
      Abstract: Hepatitis C virus (HCV)-related mixed cryoglobulinemia (MC) is a unique condition with complex pathogenesis that involves HCV antigen-driven B-lymphocyte clonal proliferation and mutagenesis. Clinical spectrum of MC ranges from asymptomatic state to clinically-apparent vasculitis involving multiple organs. In the era of direct-acting antiviral (DAA) therapy, patients with HCV-related MC achieve high rates of viral clearance that is commonly accompanied by an improvement in clinical symptoms as well as immunological profiles.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-21
      DOI: 10.1016/j.jceh.2017.11.012
  • Living Donor Liver Transplantation for Acute on Chronic Liver Failure
           Based on EASL-CLIF Diagnostic Criteria
    • Authors: Abu Bakar H. Bhatti; Faisal S. Dar, Muhammad O. Butt, Eraj Sahaab, Mohammad Salih, Najmul H. Shah, Nusrat Y. Khan, Haseeb H. Zia, Eitzaz U. Khan, Nasir A. Khan
      Abstract: The European association for the study of the liver and chronic liver failure consortium (EASL-CLIF) recently proposed diagnostic criteria for acute on chronic liver failure (ACLF). There is lack of data regarding liver transplant outcomes in ACLF patients based on these criteria. The objective of this study was to determine outcome following living donor liver transplantation (LDLT) in ACLF patients.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-06
      DOI: 10.1016/j.jceh.2017.11.007
  • Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis
           on Fibrosis and Severity of Liver Disease: A Real Life Experience from a
           Tertiary Care Center of North India
    • Authors: Gaurav Garg; Vinod K. Dixit, Sunit K. Shukla, Sudhir K. Singh, Shivam Sachan, Anurag Tiwari, Vinod K. Yadav, Dawesh P. Yadav
      Abstract: Treatment of chronic hepatitis C infection with direct-acting antiviral (DAA) drugs has been highly effective, but data regarding benefit in advanced liver disease is relatively scarce in Indian patients. The aim of this study was to determine the effects of DAA in patients with HCV related cirrhosis (compensated/decompensated) who achieved sustained virological response post-therapy at 12 weeks (SVR12).
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-04
      DOI: 10.1016/j.jceh.2017.11.011
  • High Prevalence of Cirrhosis at Initial Presentation Among Safety-Net
           Adults with Chronic Hepatitis B Virus Infection
    • Authors: Elaine Tang; Sharon Torres, Benny Liu, Rachel Baden, Taft Bhuket, Robert J. Wong
      Abstract: Delays in diagnosis of chronic hepatitis B virus infection (HBV) may be more common among underserved safety-net populations, contributing to more advanced disease at presentation. We aim to evaluate rates of and predictors of cirrhosis and cirrhosis-related complications among adults with chronic HBV.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-03
      DOI: 10.1016/j.jceh.2017.11.009
  • Patient Acceptance of Lactulose Varies Between Indian and American
           Cohorts: Implications for Comparing and Designing Global Hepatic
           Encephalopathy Trials
    • Authors: Sahaj Rathi; Andrew Fagan, James B. Wade, Madhu Chopra, Melanie B. White, Dinesh Ganapathy, Chathur Acharya, Radha K. Dhiman, Jasmohan S. Bajaj
      Abstract: Lactulose is the first-line drug for hepatic encephalopathy (HE), but its acceptance widely differs between Western and Eastern studies. Patient preference for lactulose between different parts of the world has not been examined systematically.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-02
      DOI: 10.1016/j.jceh.2017.11.010
  • A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial
           of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely
           Decompensated Cirrhosis
    • Authors: Gautam Mehta; Sam Rousell, Gary Burgess, Mark Morris, Gavin Wright, Stuart McPherson, Catherine Frenette, Matthew Cave, David T. Hagerty, Alfred Spada, Rajiv Jalan
      Abstract: Cirrhosis and acute-on-chronic liver failure (ACLF) are associated with systemic inflammation, and caspase-mediated hepatocyte cell death. Emricasan is a novel, pan-caspase inhibitor. Aims of this study were to assess the pharmacokinetics, pharmacodynamics, safety and clinical outcomes of emricasan in acute decompensation (AD) of cirrhosis.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-01
      DOI: 10.1016/j.jceh.2017.11.006
  • Acute on Chronic Liver Failure—In-Hospital Predictors of Mortality
           in ICU
    • Authors: Sujay Kulkarni; Mithun Sharma, Padaki N. Rao, Rajesh Gupta, Duvvuru N. Reddy
      Abstract: We studied in-hospital predictors of mortality of acute on chronic liver failure (ACLF) in Indian patients.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-30
      DOI: 10.1016/j.jceh.2017.11.008
  • A 4-Week-old Neonate with Jaundice and Hepatosplenomegaly
    • Authors: Geok C. Tan; Melissa Stalling, Bonita Fung
      Abstract: This is a 4-week-old girl born prematurely at 35 weeks gestation to a 15-year-old G1P0 mother after an uncomplicated pregnancy. There is a history of consanguinity. She had jaundice at birth and was treated with phototherapy but it did not resolve. Her development was appropriate for age. At follow-up, she was found to have direct hyperbilirubinemia, hepatomegaly, mild splenomegaly and a suspicious liver lesion on ultrasound. A liver biopsy was performed. Figure 1 provided shows the hepatic parenchyma stained by H&E (A), Periodic Acid Schiff (PAS) with diastase digestion (B) and CD163 (an activated macrophage marker) (C), and a figure of transmission electron microscopy of the liver (D).
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-30
      DOI: 10.1016/j.jceh.2017.11.004
  • Portal Hypertension in a Patient With Recurrent Pancreatic Cancer After
           Radiotherapy and Systemic Chemotherapy
    • Authors: Xingshun Qi; Ji Feng, Xiaodong Shao, Ying Xu, Hongyu Li, Xiaozhong Guo
      Abstract: Portal hypertension secondary to pancreatic cancer is rare in everyday clinical practice.1 The potential mechanism of disease should be portal and splenic vein involvement from pancreatic cancer. This abnormality is also termed as sinistral or left-sided portal hypertension presenting with isolated gastric varices, splenomegaly, and normal liver function. Notably, portal hypertension related complications are often the initial clinical presentations at the diagnosis of pancreatic cancer.2 However, to the best of our knowledge, few studies reported the dynamic evolution of portal hypertension after non-surgical treatment of pancreatic cancer.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-22
      DOI: 10.1016/j.jceh.2017.11.005
  • Endoscopic Cyanoacrylate Glue Injection in Management of Gastric Variceal
           Bleeding: US Tertiary Care Center Experience
    • Authors: Subhash Chandra; Adrian Holm, Rami G. El Abiad, Henning Gerke
      Abstract: Although endoscopic cyanoacrylate glue injection (ECGI) is recommended as first-line treatment for bleeding gastric varices (GV) there is still limited experience with this method in the US. Our aim was to analyze our 10-year experience of ECGI for treatment and prophylaxis of gastric variceal bleeding.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-22
      DOI: 10.1016/j.jceh.2017.11.002
  • Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With
           End Stage Renal Disease on Hemodialysis: A Single Center Experience from
    • Authors: Ankur Gupta; Puneet Arora, Priyanka Jain
      Abstract: Hepatitis C infection is known to increase the morbidity in patients with end stage renal disease (ESRD). Interferon based treatment is poorly tolerated and has limited cure rates in these patients. In limited available data, sofosbuvir based regimens have been shown to have favorable outcomes in these patients.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-20
  • Ideal Cure for Hepatitis B Infection: The Target is in Sight
    • Authors: Shrihari A. Anikhindi; Ashish Kumar, Praveen Sharma, Vikas Singla, Naresh Bansal, Anil Arora
      Abstract: Hepatitis B virus (HBV) is one of the most common causes of liver cirrhosis and hepatocellular carcinoma. Despite recent strides in pharmacotherapy, complete cure of HBV infection still remains an enigma. The biggest obstacle in HBV therapy is clearance of covalently closed circular deoxyribonucleic acid (cccDNA). We discuss about the role of cccDNA in HBV life cycle, efficacy and shortcomings of currently available antivirals as well as promising novel targets to achieve ideal HBV cure.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-16
  • Diagnostic Value of Glypican3, Heat Shock Protein 70 and Glutamine
           Synthetase in Hepatocellular Carcinoma Arising in Cirrhotic and
           Non-Cirrhotic Livers
    • Authors: Preithy Uthamalingam; Ashim Das, Arunanshu Behra, Naveen Kalra, Yogesh Chawla
      Abstract: Histopathological distinction of various nodular lesions in liver with sufficient sensitivity and specificity is a challenge even in an expert set up. The panel of immunohistochemical markers composed of glutamine synthetase (GS), Glypican3 (GPC3) and heat shock protein 70 (HSP70) was recommended by the International Consensus Group for Hepatocellular Neoplasia group for the differentiation of high grade dysplastic nodule and early hepatocellular carcinoma (HCC). The panel has been extensively validated in the western population.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-26
      DOI: 10.1016/j.jceh.2017.09.005
  • Upper Gastrointestinal Bleed Due to Invasive Hepatocellular Carcinoma and
           Hepato-Gastric Fistula
    • Authors: Abhijith Bale; Shiran Shetty, Anurag Shetty, Girisha Balaraju, Cannanore Ganesh Pai
      Abstract: A 69-year-old man with cirrhosis of the liver, possibly secondary to nonalcoholic fatty liver disease (NAFLD) and multifocal hepatocellular carcinoma (HCC) post three sessions of transcatheter arterial chemoembolization (TACE) in the past 8 months presented with upper gastrointestinal (UGI) bleed. The last session of TACE was performed two months prior to the presentation. After initial hemodynamic resuscitation an UGI endoscopy was performed which showed a large antral opening at the lesser curvature of the stomach, 3–4cm proximal to the pylorus with an ulcer at its mouth (Figure 1).
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-21
      DOI: 10.1016/j.jceh.2017.09.006
  • Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration: A New Modality
           to Diagnose Peritoneal Tuberculosis in Presence of Decompensated
           Cirrhosis—A Case Series and Review of Literature
    • Authors: Ravi Daswani; Ashish Kumar, Vikas Singla, Gagandeep Kaur, Praveen Sharma, Naresh Bansal, Anil Arora
      Abstract: The gold-standard for diagnosis is growth of Mycobacterium tuberculosis on ascitic fluid or peritoneal culture. Due to the non-specific signs and symptoms of disease, its early diagnosis is difficult, especially in patients with decompensated cirrhosis. The reported sensitivity of ascitic fluid is low and to obtain tissue for peritoneal biopsy in patients with cirrhosis is difficult. Endoscopic ultrasound (EUS) guided fine needle aspiration (FNA) is a good alternative to obtain peritoneal tissue for establishing the diagnosis of peritoneal TB.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-19
      DOI: 10.1016/j.jceh.2017.09.007
  • A Tale Of Two Diseases Or A Story Of Co-Existence: Are Obese
           Individuals’ Immune To Alcoholic Liver Disease'
    • Authors: Ankur Gupta
      Abstract: I read with interest the article by Mehta et al. in recent issue of the journal and wish to congratulate the authors for their study.1 This study may have implications in management of obese patients with alcoholic liver disease (ALD).
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-14
      DOI: 10.1016/j.jceh.2017.09.002
  • Prevalence and Impact of Bacterial Infections in Children With Liver
           Disease—A Prospective Study
    • Authors: Rishi Bolia; Anshu Srivastava, Rungmei Marak, Surender K. Yachha, Ujjal Poddar
      Abstract: Risk of infections is increased in patients with acute liver failure (ALF) and decompensated chronic liver disease (DCLD). We evaluated the frequency, site, type and risk-factors for bacterial infections in children with ALF and DCLD and its effect on outcome.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-07
      DOI: 10.1016/j.jceh.2017.08.007
  • Acute Exacerbation Of Autoimmune Hepatitis Mimicking Acute Viral
           Hepatitis—A Case Series and Review of Literature
    • Authors: Sunil Taneja; Pramod Kumar, Suvradeep Mitra, Ajay Duseja, Ranjana Minz, Ashim Das, Radha K. Dhiman, Yogesh Chawla
      Abstract: Acute exacerbation of autoimmune hepatitis (AIH) poses a significant challenge for diagnosis as it can mimic acute viral hepatitis especially in absence of autoantibodies and hypergammaglobulinemia.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-09-21
      DOI: 10.1016/j.jceh.2017.08.005
  • A Case of Acute-On-Chronic Liver Failure (ACLF) Due To An Uncommon Acute
           And Chronic Event
    • Authors: Swastik Agrawal; Baldev S. Rana, Suvradeep Mitra, Ajay Duseja, Ashim Das, Radha K. Dhiman, Yogesh Chawla
      Abstract: Acute on chronic liver failure (ACLF) is an acute worsening of patients with chronic liver disease resulting in liver failure. Usually these patients have cirrhosis as the underlying liver disease with alcohol being the most common etiology. Common hepatitic illnesses causing acute worsening in Indian patients of ACLF include alcoholic hepatitis, acute viral hepatitis related to hepatitis E virus and acute flare in chronic hepatitis B. We report an adult case of ACLF due acute viral hepatitis related to hepatitis A virus infection superimposed on nonalcoholic steatohepatitis without cirrhosis.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-09-10
      DOI: 10.1016/j.jceh.2017.08.006
  • Efficacy And Safety of Sofosbuvir Based Regimens For Treatment of
           Hepatitis C Recurrence After Living Donor Liver Transplantation: An
           Experience From India
    • Authors: Narendra S. Choudhary; Sanjiv Saigal, Dheeraj Gautam, Neeraj Saraf, Amit Rastogi, Sanjay Goja, Prashant Bhangui, Arvinder S. Soin
      Abstract: Results of Sofosbuvir based regimens for hepatitis C (HCV) recurrence after liver transplantation are available from well-designed clinical trials. Most of the data is from deceased donor liver transplant (DDLT) setting, and data on “real world” experience for HCV recurrence after living donor liver transplantation (LDLT) is limited.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-09-08
      DOI: 10.1016/j.jceh.2017.08.004
  • Circulating Fibroblast Growth Factor 19 in Portal and Systemic Blood
    • Authors: Helene Johansson; Lisa-Mari Mörk, Meng Li, Anita L. Sandblom, Ingemar Björkhem, Jonas Höijer, Bo-Göran Ericzon, Carl Jorns, Stefan Gilg, Ernesto Sparrelid, Bengt Isaksson, Greg Nowak, Ewa Ellis
      Abstract: Bile acid homeostasis is essential and imbalance may lead to liver damage and liver failure. The bile acid induced intestinal factor fibroblast growth factor 19 (FGF19) has been identified as a key protein for mediating negative feedback inhibition of bile acid synthesis. The aim of the study was to define FGF19 and bile acid concentrations in portal and systemic blood in the fasted and postprandial state. We also addressed the question if physiological portal levels of FGF19 can be extrapolated from the concentration in systemic blood.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-08-09
      DOI: 10.1016/j.jceh.2017.07.001
  • Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus
           Infection in Patients with β-Thalassemia Major
    • Authors: Rajiv Mehta; Mayank Kabrawala, Subhash Nandwani, Pankaj Desai, Vishwa Bhayani, Sanjay Patel, Viral Parekh
      Abstract: β-thalassemia major patients are susceptible to hepatitis C virus (HCV) infection owing to life-long dependency for blood-transfusion. Moreover, this patient population is at risk of progression of liver fibrosis or development of cirrhosis as a consequence of both iron overload and HCV infection. Hence, this study was carried out to evaluate efficacy and safety of the combination regimen of sofosbuvir and daclatasvir for HCV infection in β-thalassemia major patients.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-07-14
      DOI: 10.1016/j.jceh.2017.06.002
  • Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4
           Patients: Promising Effect on Liver Fibrosis
    • Authors: Asmaa M. Abdel-Aziz; Mohamed A. Ibrahim, Azza A. El-Sheikh, Maha Y. Kamel, Nagwa M. Zenhom, Salam Abdel-Raheim, Hisham Abdelhaleem
      Abstract: The effect of sofosbuvir and daclatasvir in treatment of genotype 4 hepatitis C (HCV) virus is not well documented. This study investigated the safety and efficacy of sofosbuvir plus daclatasvir with or without ribavirin in treatment of HCV genotype 4 patients. The impact of therapy on liver fibrosis as well as the role of IL18 polymorphism in therapeutic outcome was assessed.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-07-07
      DOI: 10.1016/j.jceh.2017.06.006
  • Increased Incidence of Post-transplant Lymphoproliferative Disorder in
           Autoimmune Liver Disease: An Irish National Experience
    • Authors: Ahmed Abu-Shanab; Yasser Ged, Naeem Ullah, Diarmaid Houlihan, Aiden McCormick
      Abstract: Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized complication post solid organs transplant. PTLD represents a broad spectrum of abnormalities ranging from an infectious mononucleosis like illness to malignant lymphoma.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-07-06
      DOI: 10.1016/j.jceh.2017.05.209
  • Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy
           in Patients With Cirrhosis of Liver
    • Authors: Abhijith Bale; C. Ganesh Pai, Shiran Shetty, Girisha Balaraju, Anurag Shetty
      Abstract: Minimal hepatic encephalopathy (MHE), though highly prevalent, is a frequently underdiagnosed complication of cirrhosis of the liver. Because lack of time is reported as the major reason for non-testing, identifying patients at high risk of MHE would help in targeting them for screening. We aimed to determine the factors associated with MHE to help identify patient subgroups with a higher risk of MHE for targeted screening.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-07-01
      DOI: 10.1016/j.jceh.2017.06.005
  • Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C
           Genotypes 1, 3 and 4: A Real Life Experience from India
    • Authors: Varun Mehta; Ramit Mahajan, Vandana Midha, Vikram Narang, Kirandeep Kaur, Arshdeep Singh, Anand Malhotra, Aslam Parvez, Ajit Sood
      Abstract: To assess impact of direct acting antiviral (DAA) therapies for treatment of hepatitis C virus (HCV) genotypes 1, 3 and 4 in a real-world cohort from India.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-07-01
      DOI: 10.1016/j.jceh.2017.06.003
  • Living Donor Liver Transplantation Using Small-for-Size Grafts: Does Size
           Really Matter'
    • Authors: Pulkit Sethi; Manoj Thillai, Binoj Sivasankarapillai Thankamonyamma, Shweta Mallick, Unnikrishnan Gopalakrishnan, Dinesh Balakrishnan, Ramachandran Narayana Menon, Sudhindran Surendran, Puneet Dhar, Sudheer Othiyil Vayoth
      Abstract: In living donor liver transplantation (LDLT), graft-to-recipient weight ratio (GRWR)>0.8% is perceived as the critical graft size. This lower limit of GRWR (0.8%) has been challenged over the last decade owing to the surgical refinements, especially related to inflow and outflow modulation techniques. Our aim was to compare the recipient outcome in small-for-size (GRWR0.8) and to determine the risk factors for mortality when small-for-size grafts (SFSG) were used.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-06-27
      DOI: 10.1016/j.jceh.2017.06.004
  • Natural History of Cirrhosis of Liver after First Decompensation: A
           Prospective Study in India
    • Authors: Apurva S. Shah; Deepak N. Amarapurkar
      Abstract: As liver cirrhosis is a dynamic condition, it is possible to improve survival in decompensated cirrhosis. Hence, we planned a prospective study to determine the natural history of cirrhosis after first decompensation.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-06-26
      DOI: 10.1016/j.jceh.2017.06.001
  • Role of Indocyanine Green in Predicting Post-Transarterial
           Chemoembolization Liver Failure in Hepatocellular Carcinoma
    • Authors: Shalimar; Sushil Jain, Shivanand R. Gamanagatti, Saurabh Kedia, Bhaskar Thakur, Baibaswata Nayak, Harpreet Kaur, Deepak Gunjan, Shashi B. Paul, Subrat K. Acharya
      Abstract: Post-transarterial chemoembolization (TACE) liver failure (LF) is common in patients with hepatocellular carcinoma (HCC). No definitive objective parameters predict its occurrence. We assessed the role of indocyanine green (ICG) in prediction of post-TACE LF.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-06-16
      DOI: 10.1016/j.jceh.2017.05.012
  • Role of Glutathione S Transferase M1 and T1 Gene Polymorphism in Hepatitis
           B Related Liver Diseases and Cryptogenic Cirrhosis
    • Authors: Siddharth Kapahtia; Rajib K. Hazam, Mohammad Asim, Vijay K. Karra, Soumya J. Chowdhury, Bhudev C. Das, Premashis Kar
      Abstract: Progression of hepatitis B virus infection (HBV) might be affected by host genetic factors. The present study was undertaken to study the role of glutathione S-transferases (GST)-M1 and T1 gene polymorphisms in different stages of HBV infection: HBV inactive carrier, chronic hepatitis B and cirrhosis, and cryptogenic cirrhosis.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-06-11
      DOI: 10.1016/j.jceh.2017.05.208
  • Bone Health and Impact of Tenofovir Treatment in Men with Hepatitis-B
           Related Chronic Liver Disease
    • Authors: Kattiparambil G. Sajith; Nitin Kapoor, Sahana Shetty, Ashish Goel, Uday Zachariah, Chundamannil E. Eapen, Thomas V. Paul
      Abstract: Chronic liver disease (CLD) has been shown to have an adverse impact on bone health. Hepatitis-B related CLD and its treatment with tenofovir may have additional effects on skeleton.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-05-26
      DOI: 10.1016/j.jceh.2017.05.009
  • Can Non-Selective Beta-Blockers (NSBBs) Prevent Enlargement of Small
           Esophageal Varices in Patients with Cirrhosis' A Meta-analysis
    • Authors: Ashish Kumar; Praveen Sharma, Shrihari A. Anikhindi, Ritesh Prajapati, Rachit Agarwal, Bhupendra Sharma, Naresh Bansal, Vikas Singla, Anil Arora
      First page: 275
      Abstract: Non-selective beta-blockers (NSBBs) are recommended for prophylaxis of first variceal bleeding in patients of cirrhosis with large esophageal varices. However, the data is conflicting whether NSBBs can also prevent growth of small esophageal varices to large size.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-14
      DOI: 10.1016/j.jceh.2017.09.003
  • Thromboelastography for Assessing the Risk of Bleeding in Patients With
           Cirrhosis—Moving Closer
    • Authors: Vaibhav Somani; Deepak Amarapurkar, Apurva Shah
      First page: 284
      Abstract: Conventional coagulation tests (CCTs) in patients with cirrhosis only assess procoagulant factors and are poor predictors of bleeding risk. In spite of this knowledge, they are routinely used prior to invasive procedures, and attempts are made to correct these abnormalities before invasive procedures. These practices are not supported by the evidence and are harmful to the patients.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-04-21
      DOI: 10.1016/j.jceh.2017.03.001
  • Impact of Acute Kidney Injury on Mortality of Patients Hospitalized for
           Complications of Cirrhosis
    • Authors: Anantha Nuthalapati; Nicholas Schluterman, Anuj Khanna, Deborah Greenberg, Paul J. Thuluvath
      First page: 290
      Abstract: The mortality of hospitalized patients for complications of cirrhosis is very high. We examined the independent predictors of mortality, particularly the impact of increments in creatinine, in 339 consecutive patients (636 admissions) who were admitted for complications of cirrhosis.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-05-25
      DOI: 10.1016/j.jceh.2017.05.004
  • Results of Portosystemic Shunt Embolization in Selected Patients with
           Cirrhosis and Recurrent Hepatic Encephalopathy
    • Authors: Narendra S. Choudhary; Sanjay Saran Baijal, Sanjiv Saigal, Amit Agarwal, Neeraj Saraf, Rohit Khandelwal, Vaibhav Jain, Anubhav Harish Khandelwal, Abhay Kapoor, Deepak Jain, Smurti R. Misra, Rajesh Puri, Randhir Sud, Arvinder S. Soin
      First page: 300
      Abstract: Large portosystemic shunts (PSSs) may lead to recurrent encephalopathy in patients with cirrhosis and embolization of these shunts may improve encephalopathy.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-04-27
      DOI: 10.1016/j.jceh.2017.03.012
  • An Insight into Antibiotic Resistance to Bacterial Infection in Chronic
           Liver Disease
    • Authors: Mayank Jain; Joy Varghese, Tom Michael, Chandan Kumar Kedarishetty, Balajee G, Subramanian Swaminathan, Jayanthi Venkataraman
      First page: 305
      Abstract: End stage liver disease leads to immune dysfunction which predisposes to infection. There has been a rise in antibiotic resistant infections in these patients. There is scanty data f from India or idea regarding the same.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-05-23
      DOI: 10.1016/j.jceh.2017.05.003
  • Simple Anthropometric Indices are Useful for Predicting Non-alcoholic
           Fatty Liver Disease [NAFLD] in Asian Indians
    • Authors: Ayaskanta Singh; Sasmita Parida, Jimmy Narayan, Preetam Nath, Pradeep K. Padhi, Girish K. Pati, Prasanta K. Parida, Chudamani Meher, Omprakash Agrawal, Shivaram P. Singh
      First page: 310
      Abstract: With the rising prevalence of obesity and metabolic syndrome, nonalcoholic fatty liver disease (NAFLD) has become the most common liver disorder in both developed and developing nations. Several studies on NAFLD have described waist circumference, a surrogate marker of visceral fat accumulation and waist height ratio as a better screening tool for NAFLD and metabolic syndrome than body mass index (BMI). We conducted this study to assess simple abdominal obesity indices as a predictor of NAFLD and determine the appropriate cut-off levels with reference to NAFLD.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-05-25
      DOI: 10.1016/j.jceh.2017.05.005
  • Glycochenodeoxycholic Acid Does Not Increase Transforming Growth
           Factor-Beta Expression in Bile Duct Epithelial Cells or Collagen Synthesis
           in Myofibroblasts
    • Authors: Anna Wang; Dorothy Yu, Yuewen Gong, Jessie Garber, Gerald Y. Minuk
      First page: 316
      Abstract: Primary sclerosing cholangitis (PSC) is a chronic, progressive hepatobiliary disorder characterized by extensive fibrosis and stricturing of the intra- and/or extra-hepatic bile ducts: Previous studies have documented low phosphatylcholine (PC) concentrations in PSC bile. The aim of this study was to determine whether low PC levels in bile facilitate toxic bile acid induced injury of biliary tract epithelial cells resulting in enhanced transforming growth factor-beta (TGF-β) expression and increased collagen synthesis by myofibroblasts.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-05-23
      DOI: 10.1016/j.jceh.2017.04.002
  • Echocardiographic and Electrocardiographic Predictors of Adverse Outcomes
           in Spontaneous Bacterial Peritonitis
    • Authors: Mahek Shah; Soumya Patnaik, Obiora Maludum, Shantanu Patil, Toni Anne De Venecia, Vincent M. Figueredo
      First page: 321
      Abstract: Patients with cirrhosis who develop spontaneous bacterial peritonitis (SBP) suffer from cirrhotic cardiomyopathy which is characterized by impaired contractility in response to stress despite a relatively normal resting cardiac output. We hypothesized that electrocardiographic and echocardiographic information would help prognosticate patients developing SBP in addition to existing scoring systems.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-05-25
      DOI: 10.1016/j.jceh.2017.05.007
  • Long Term Outcomes of Patients with Significant Biliary Obstruction Due to
           Portal Cavernoma Cholangiopathy and Extra-Hepatic Portal Vein Obstruction
           (EHPVO) With No Shuntable Veins
    • Authors: Akash Shukla; Amit Gupte, Vedant Karvir, Prashant Dhore, Shobna Bhatia
      First page: 328
      Abstract: The natural history of portal cavernoma cholangiopathy (PCC) in patients with significant biliary obstruction (SBO) who cannot undergo shunt surgery, is not known. We therefore, analyzed data of patients of extra-hepatic portal venous obstruction (EHPVO) with PCC.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-05-26
      DOI: 10.1016/j.jceh.2017.04.003
  • Prevalence and Characteristics of Hepatitis Delta Virus Infection in a
           Tertiary Hospital Setting in Cameroon
    • Authors: Henry N. Luma; Servais A.F.B. Eloumou, Cécile Okalla, Olivier Donfack-Sontsa, Ruth Koumitana, Agnes Malongue, Georges B. Nko’Ayissi, Dominique N. Noah
      First page: 334
      Abstract: Hepatitis B virus (HBV) and hepatitis D virus (HDV) coinfection is associated with more severe liver disease than HBV alone. More knowledge on the epidemiology and clinical impact of HDV-infected individuals is needed in Cameroon.We aimed at determining the frequency of anti-HDV antibody testing in hepatitis B surface antigen (HBsAg) positive patients, the proportion of anti-HDV positivity, and the characteristics of anti-HDV positive compared to anti-HDV negative patients in a tertiary hospital setting in Cameroon.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-06-01
      DOI: 10.1016/j.jceh.2017.05.010
  • Nutrition and Muscle in Cirrhosis
    • Authors: Anil C. Anand
      First page: 340
      Abstract: As the cirrhosis progresses, development of complication like ascites, hepatic encephalopathy, variceal bleeding, kidney dysfunction, and hepatocellular carcinoma signify increasing risk of short term mortality. Malnutrition and muscle wasting (sarcopenia) is yet other complications that negatively impact survival, quality of life, and response to stressors, such as infection and surgery in patients with cirrhosis. Conventionally, these are not routinely looked for, because nutritional assessment can be a difficult especially if there is associated fluid retention and/or obesity.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-16
      DOI: 10.1016/j.jceh.2017.11.001
  • Acute and Chronic Rejection After Liver Transplantation: What A Clinician
           Needs to Know
    • Authors: Narendra S. Choudhary; Sanjiv Saigal, Rinkesh K. Bansal, Neeraj Saraf, Dheeraj Gautam, Arvinder S. Soin
      First page: 358
      Abstract: While antibody mediated hyper-acute vasculitic rejection is rare in liver transplant recipients, acute and chronic rejection have clinical significance. The liver allograft behaves differently to other solid organ transplants as acute rejection generally does not impair graft survival and chronic rejection (CR) is uncommon. The incidence of acute and chronic rejection has declined in current era due to improved immunosuppressive regimens. Acute rejection generally improves with steroid boluses and steroid resistant rejection is uncommon.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-20
  • Matrix Metalloproteinases (MMPs) in Liver Diseases
    • Authors: Adnan Naim; Qiuwei Pan, Mirza S. Baig
      First page: 367
      Abstract: Matrix metalloproteinases (MMPs) are proteinases capable of degrading components of the extracellular matrix and numerous nonmatrix proteins. MMPs along with tissue inhibitors of MMPs, have been implicated in the pathogenesis of liver diseases. Although, the precise mechanism-of-actions of MMPs in various liver related disorders is largely unknown, however, data from diverse experimental models indicate that these proteinases influence cellular activities including proliferation and survival, gene expression, as well as multiple aspects of inflammation.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-18
      DOI: 10.1016/j.jceh.2017.09.004
  • Cholemic or Bile Cast Nephropathy in a Child with Liver Failure
    • Authors: Vikrant Sood; Bikrant B. Lal, Suman Lata, Archana Rastogi, Seema Alam
      First page: 373
      Abstract: Cholemic or bile cast nephropathy is an under-reported entity characterized by acute renal dysfunction in patients with hepatic insult. Limited literature is available regarding its clinical presentation, pathogenesis and prognosis. We hereby present a pediatric case who presented with acute on chronic liver failure with renal dysfunction secondary to cholemic nephropathy.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-05-24
      DOI: 10.1016/j.jceh.2017.05.006
  • Middle Hepatic Vein Bleed During Donor Hepatectomy: Technique for Safe
    • Authors: Madhusudhanan Jegadeesan; Neerav Goyal, Subash Gupta
      First page: 376
      Abstract: Safe performance of donor hepatectomy is crucial for sustainability of a living donor liver transplantation (LDLT) program. Middle hepatic vein (MHV) is always encountered during parenchymal transection irrespective of right or left donor hepatectomies. Here we present a safe and effective technique for tackling MHV bleed during LDLT from a single centre experience.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-06-02
      DOI: 10.1016/j.jceh.2017.05.008
  • A Rare Case of Primary Sarcomatous Hepatocellular Carcinoma Without
           Previous Anticancer Therapy
    • Authors: Suvradeep Mitra; Saumya Gupta, Divya Dahiya, Uma N. Saikia
      First page: 378
      Abstract: Primary sarcomatous hepatocellular carcinoma (PSHCC) is a rare and aggressive variety of hepatocellular carcinoma (HCC). The recent evidence suggests that anticancer therapy promotes the dedifferentiation of the carcinomatous component and is largely responsible for this aggressive variant of HCC. However, in the absence of any anticancer therapy, occurrence of PSHCC is extremely rare. Herein, we present a rare case report of a 65 year old male patient, with a hepatitis B positive status, presenting with PSHCC without any history of anticancer therapy.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-03-24
      DOI: 10.1016/j.jceh.2017.03.008
  • Large Heterogeneous Calcified Masses in Liver: A Diagnostic Dilemma
    • Authors: Nidhi Prabhakar; Naveen Kalra, Arunanshu Behera, Ashim Das, Anupam Lal, Radha Krishan Dhiman, Niranjan Khandelwal
      First page: 385
      Abstract: A 27-year-old female presented to our hospital with complaints of jaundice and epigastric pain. The patient had history of progressive cholestatic jaundice for the last 3 months. She was also suffering from continuous epigastric pain for the last 1 month. General physical examination revealed icterus. On palpation, hepatomegaly was noted. Laboratory investigations revealed mild anaemia (10g/dl), increased white blood counts (13,000/mm3) and normal platelet count (380×103/mm3). Liver function tests were abnormal (increased total serum bilirubin 8mg/dl, serum alkaline phosphatase 1000IU/L, serum alanine aminotransferase 110IU/L, aspartate aminotransferase 100IU/L).
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-27
      DOI: 10.1016/j.jceh.2017.09.001
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
Home (Search)
Subjects A-Z
Publishers A-Z
Your IP address:
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016